Per Wold-Olsen

Filings by Per Wold-Olsen span 2 companies, the busiest being Oncopeptides AB and Senzime AB (publ.). We count 57 filings; the first trade dates from 18 May 2018 and the latest from 9 June 2026.

The open-market record is one-sided, with 49 purchases worth €1.6M and not one sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Besides market trades, the filings include 4 share grants.

A typical purchase (the median) is worth €5,169. 2 out of 28 purchases came within 30 days of a purchase by at least one other insider of the same company. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase.

The record was last updated on 9 June 2026 with a share grant in Oncopeptides AB. The most recent open-market purchase was published on 23 September 2025, 397 days ago. The median gap between a trade and its publication by Finansinspektionen is 1 day. Under the Market Abuse Regulation, managers have three business days to notify their trades. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.